Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

被引:31
作者
Liu, Xiaolei [1 ]
Li, Yan [1 ,2 ]
Wu, Kaichun [3 ,4 ]
Shi, Yongquan [3 ,4 ]
Chen, Min [3 ,4 ]
机构
[1] Air Force Med Univ, Xijing Hosp, Dept Med Insurance, Xian 710032, Shaanxi, Peoples R China
[2] Qinghai Univ, Affiliated Hosp, Dept Gastroenterol, Xining 810001, Qinghai, Peoples R China
[3] Air Force Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China
[4] Air Force Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
REMISSION;
D O I
10.1155/2021/6612970
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim. Increasing evidence supports the role of the gut microbiota in the etiology of ulcerative colitis (UC). Fecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection; however, its efficacy in UC is still controversial. A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of FMT for treatment of active UC. Methods. We searched Cochrane, Medline, Web of Science, and Embase from inception to February 2020. Randomized controlled trials (RCTs) recruiting adults with active UC, which compared FMT with controls, were eligible. The primary outcome was combined clinical remission with endoscopic remission/response. Secondary outcomes included clinical remission, endoscopic remission, and serious adverse events. Relative risk (RR) with 95% confidence interval (CI) is reported. Results. Five RCTs with 292 participants were eligible for inclusion. When data were pooled for all patients, FMT was associated with a higher combined clinical remission with endoscopic remission/response; the RR of combined outcome not achieving after FMT vs. control was 0.79 (95% CI 0.70-0.88). FMT delivered via lower gastrointestinal route was superior to upper gastrointestinal route with regard to combined clinical remission with endoscopic remission/response (RR=0.79, 95% CI 0.70-0.89). FMT with pooled donor stool (RR=0.69, 95% CI 0.56-0.85) and higher frequency of administration (RR=0.76, 95% CI 0.62-0.93) may be more effective with regard to clinical remission. There was no statistically significant difference in serious adverse events with FMT compared with controls (RR=0.98, 95% CI 0.93-1.03). Conclusion. FMT shows a promising perspective with comparable safety and favorable clinical efficacy for the treatment of active UC in the short term. However, further larger, more rigorously conducted RCTs of FMT in UC are still needed in order to resolve the controversial questions.
引用
收藏
页数:13
相关论文
共 32 条
[1]  
BENNET JD, 1989, LANCET, V1, P164
[2]   Efficacy and safety of fecal microbiota transplantation by washed preparation in patients with moderate to severely active ulcerative colitis [J].
Chen, Min ;
Liu, Xiao Lei ;
Zhang, Yu Jie ;
Nie, Yong Zhan ;
Wu, Kai Chun ;
Shi, Yong Quan .
JOURNAL OF DIGESTIVE DISEASES, 2020, 21 (11) :621-628
[3]   Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis A Randomized Clinical Trial [J].
Costello, Samuel P. ;
Hughes, Patrick A. ;
Waters, Oliver ;
Bryant, Robert, V ;
Vincent, Andrew D. ;
Blatchford, Paul ;
Katsikeros, Rosa ;
Makanyanga, Jesica ;
Campaniello, Melissa A. ;
Mavrangelos, Chris ;
Rosewarne, Carly P. ;
Bickley, Chelsea ;
Peters, Cian ;
Schoeman, Mark N. ;
Conlon, Michael A. ;
Roberts-Thomson, Ian C. ;
Andrews, Jane M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (02) :156-164
[4]  
Crothers J, 2018, GASTROENTEROLOGY, V154, pS1050
[5]   Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis [J].
Ding, Xiao ;
Li, Qianqian ;
Li, Pan ;
Zhang, Ting ;
Cui, Bota ;
Ji, Guozhong ;
Lu, Xiang ;
Zhang, Faming .
DRUG SAFETY, 2019, 42 (07) :869-880
[6]   Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation [J].
Fuentes, Susana ;
Rossen, Noortje G. ;
van der Spek, Mirjam J. ;
Hartman, Jorn H. A. ;
Huuskonen, Laura ;
Korpela, Katri ;
Salojarvi, Jarkko ;
Aalvink, Steven ;
de Vos, Willem M. ;
D'Haens, Geert R. ;
Zoetendal, Erwin G. ;
Ponsioen, Cyriel Y. .
ISME JOURNAL, 2017, 11 (08) :1877-1889
[7]  
Gupta Arjun, 2017, JAMA, V318, P102, DOI 10.1001/jama.2017.6466
[8]   Quantifying heterogeneity in a meta-analysis [J].
Higgins, JPT ;
Thompson, SG .
STATISTICS IN MEDICINE, 2002, 21 (11) :1539-1558
[9]   The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J].
Higgins, Julian P. T. ;
Altman, Douglas G. ;
Gotzsche, Peter C. ;
Jueni, Peter ;
Moher, David ;
Oxman, Andrew D. ;
Savovic, Jelena ;
Schulz, Kenneth F. ;
Weeks, Laura ;
Sterne, Jonathan A. C. .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[10]   MICROBIAL COMPOSITION IS EFFECTIVELY IMPROVED BY COMBINATION THERAPY WITH FECAL MICROBIAL TRANSPLANTATION AND MULTIPLE ANTIBIOTICS FOR ULCERATIVE COLITIS [J].
Ishikawa, Dai ;
Takahashi, Masahito ;
Haga, Keiichi ;
Ito, Shoko ;
Okahara, Kouki ;
Shibuya, Tomoyoshi ;
Nagahara, Akihito .
GASTROENTEROLOGY, 2018, 154 (01) :S38-S38